BR112014003225A2 - profármacos de treprostinil ligados a veículo - Google Patents
profármacos de treprostinil ligados a veículoInfo
- Publication number
- BR112014003225A2 BR112014003225A2 BR112014003225A BR112014003225A BR112014003225A2 BR 112014003225 A2 BR112014003225 A2 BR 112014003225A2 BR 112014003225 A BR112014003225 A BR 112014003225A BR 112014003225 A BR112014003225 A BR 112014003225A BR 112014003225 A2 BR112014003225 A2 BR 112014003225A2
- Authority
- BR
- Brazil
- Prior art keywords
- vehicle
- prodrugs
- linked treprostinil
- compounds
- treprostinil prodrugs
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 title abstract 3
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 title abstract 3
- 229960005032 treprostinil Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177409 | 2011-08-12 | ||
| EP11195615 | 2011-12-23 | ||
| EP12165508 | 2012-04-25 | ||
| PCT/EP2012/065745 WO2013024052A1 (en) | 2011-08-12 | 2012-08-10 | Carrier-linked treprostinil prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014003225A2 true BR112014003225A2 (pt) | 2017-03-01 |
Family
ID=46690494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014003225A BR112014003225A2 (pt) | 2011-08-12 | 2012-08-10 | profármacos de treprostinil ligados a veículo |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9561287B2 (enExample) |
| EP (1) | EP2741781A1 (enExample) |
| JP (1) | JP6092867B2 (enExample) |
| KR (1) | KR101997939B1 (enExample) |
| CN (1) | CN103857413A (enExample) |
| AU (1) | AU2012296954B2 (enExample) |
| BR (1) | BR112014003225A2 (enExample) |
| CA (1) | CA2843883C (enExample) |
| HK (1) | HK1198359A1 (enExample) |
| IL (1) | IL230712A (enExample) |
| IN (1) | IN2014CN00989A (enExample) |
| MX (1) | MX349950B (enExample) |
| WO (1) | WO2013024052A1 (enExample) |
| ZA (1) | ZA201400977B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1198359A1 (en) * | 2011-08-12 | 2015-04-10 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
| WO2013160340A1 (en) * | 2012-04-25 | 2013-10-31 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| AU2013353985B2 (en) | 2012-12-07 | 2017-07-13 | Ascendis Pharma A/S | Carrier-linked prostanoid prodrugs |
| EP3712142B1 (en) | 2013-01-11 | 2022-07-06 | Corsair Pharma, Inc. | Prodrugs of treprostinil |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| CA2908244C (en) * | 2013-03-25 | 2021-04-20 | United Therapeutics Corporation | Process of making prostacyclin compounds with linker thiol and pegylated forms |
| CA2911172C (en) | 2013-04-30 | 2021-10-19 | United Therapeutics Corporation | Controlled release pharmaceutical formulations |
| BR112016009207B1 (pt) | 2013-10-25 | 2022-11-22 | Insmed Incorporated | Compostos de prostaciclina |
| JO3624B1 (ar) * | 2014-05-08 | 2020-08-27 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| JP2017517550A (ja) * | 2014-06-13 | 2017-06-29 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニル製剤 |
| EP3169660A1 (en) * | 2014-07-16 | 2017-05-24 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| CA2967385C (en) | 2014-11-18 | 2023-05-16 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| TWI540121B (zh) | 2014-12-01 | 2016-07-01 | 臺灣永光化學工業股份有限公司 | 曲前列環素二乙醇胺之合成方法及新穎中間體 |
| IL252577B (en) | 2014-12-03 | 2022-07-01 | Steadymed Ltd | Preservative-free treprostinil formulations and methods and devices for use with same |
| US9643911B2 (en) * | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US11389510B2 (en) | 2016-01-08 | 2022-07-19 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
| IL297375B2 (en) | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low NPR–C binding |
| EP3400018A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
| IL259658B2 (en) | 2016-01-08 | 2024-06-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with reduced side-effects |
| PL3400019T3 (pl) | 2016-01-08 | 2023-01-23 | Ascendis Pharma Growth Disorders A/S | Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy |
| MX2018008061A (es) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. |
| FI3423103T3 (fi) | 2016-03-01 | 2024-11-20 | Ascendis Pharma Bone Diseases As | PTH-aihiolääkkeitä |
| US11896671B2 (en) | 2016-07-13 | 2024-02-13 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
| DK3512495T3 (da) * | 2016-09-15 | 2022-12-05 | Camurus Ab | Formuleringer af prostacyklinanaloger |
| CN109789188B (zh) | 2016-09-29 | 2023-07-14 | 阿森迪斯药物骨疾病股份有限公司 | 具有低峰-谷比的pth化合物 |
| MY199903A (en) | 2016-09-29 | 2023-11-28 | Ascendis Pharma Growth Disorders As | Combination therapy with controlled-release cnp agonists |
| DK3518960T5 (da) | 2016-09-29 | 2024-09-02 | Ascendis Pharma Bone Diseases As | Doseringsskema for en PTH-forbindelse med kontrolleret frigivelse |
| HRP20250102T1 (hr) | 2016-09-29 | 2025-03-28 | Ascendis Pharma Bone Diseases A/S | Pth spojevi s kontroliranim oslobađanjem |
| EP3498283A1 (en) | 2017-12-14 | 2019-06-19 | Ipsol AG | Glycosidic derivatives of treprostinil |
| BR112020022306A2 (pt) | 2018-05-18 | 2021-02-23 | Ascendis Pharma Bone Diseases A/S | dose de partida de conjugados de pth |
| WO2020064847A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Degradable hyaluronic acid hydrogels |
| MX2021003186A (es) | 2018-09-26 | 2021-07-16 | Ascendis Pharma As | Nuevos conjugados de hidrogel. |
| CA3114056A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Treatment of infections |
| MX2021007706A (es) | 2019-01-04 | 2021-08-05 | Ascendis Pharma Oncology Div A/S | Conjugados de agonistas de receptor de reconocimiento de patron. |
| SG11202105833WA (en) | 2019-01-04 | 2021-07-29 | Ascendis Pharma Oncology Div A/S | Minimization of systemic inflammation |
| JP2022516314A (ja) | 2019-01-04 | 2022-02-25 | アセンディス ファーマ オンコロジー ディヴィジョン エー／エス | 自然免疫アゴニストのための持続性局所性薬物レベル |
| EP3906018A1 (en) | 2019-01-04 | 2021-11-10 | Ascendis Pharma Oncology Division A/S | Induction of sustained local inflammation |
| KR20250171437A (ko) | 2019-02-11 | 2025-12-08 | 아센디스 파마 본 디지즈 에이/에스 | Pth 접합체의 액체 약학 제제 |
| KR102893903B1 (ko) | 2019-02-11 | 2025-12-01 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | Cnp 접합체의 건조 약학 제제 |
| KR20220002600A (ko) | 2019-04-29 | 2022-01-06 | 인스메드 인코포레이티드 | 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법 |
| US20230102309A1 (en) | 2019-06-21 | 2023-03-30 | Ascendis Pharma Oncology Division A/S | Tyrosine kinase inhibitor conjugates |
| WO2020254617A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pk properties |
| WO2020254612A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pd properties |
| WO2020254607A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pd properties |
| WO2020254613A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pk properties |
| EP3986479A1 (en) | 2019-06-21 | 2022-04-27 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 conjugates |
| JP2020011957A (ja) * | 2019-07-22 | 2020-01-23 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| BR112022010419A2 (pt) | 2020-01-13 | 2022-08-23 | Ascendis Pharma Bone Diseases As | Tratamento de hipoparatireoidismo |
| AU2021269007A1 (en) | 2020-05-04 | 2022-11-24 | Ascendis Pharma A/S | Hydrogel irradiation |
| US11793780B2 (en) * | 2020-06-09 | 2023-10-24 | United Therapeutics Corporation | Prodrugs of treprosiinil |
| MX2023003540A (es) | 2020-09-28 | 2023-04-21 | Ascendis Pharma Bone Diseases As | Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo. |
| JP7138685B2 (ja) * | 2020-10-26 | 2022-09-16 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| WO2022194195A1 (zh) * | 2021-03-16 | 2022-09-22 | 江苏恒瑞医药股份有限公司 | 一种曲前列环素衍生物及其用途 |
| KR20240082355A (ko) | 2021-09-22 | 2024-06-10 | 아센디스 파마 본 디지즈 에이/에스 | 장시간 작용형 pth 화합물 치료 |
| WO2023110727A2 (en) | 2021-12-13 | 2023-06-22 | Ascendis Pharma Oncology Division A/S | Novel cancer treatments with tlr7/8 agonists |
| WO2023110758A1 (en) | 2021-12-13 | 2023-06-22 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
| CN116444377A (zh) * | 2022-01-07 | 2023-07-18 | 广州楷石医药有限公司 | 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途 |
| CA3249311A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS |
| JP2025537527A (ja) | 2022-11-02 | 2025-11-18 | アセンディス ファーマ ボーン ディジージズ エー／エス | ２つのｐｔｈ化合物を含むｐｔｈ治療レジメン |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| CN121219011A (zh) | 2023-03-20 | 2025-12-26 | 阿森迪斯药物生长障碍股份有限公司 | 治疗患有软骨发育不全患者胸腰椎畸形的方法 |
| WO2025051711A1 (en) | 2023-09-04 | 2025-03-13 | Ascendis Pharma Bone Diseases A/S | Pth treatment of chronic kidney disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| CA1241324A (en) | 1984-03-08 | 1988-08-30 | Paul A. Aristoff | Interphenylene carbacyclin derivatives |
| AU4327300A (en) | 1999-03-31 | 2000-10-16 | United Therapeutics Corporation | Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension |
| JP4698579B2 (ja) * | 2003-04-08 | 2011-06-08 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 可逆的ｐｅｇ化薬物 |
| DE602004022982D1 (de) * | 2003-12-16 | 2009-10-15 | United Therapeutics Corp | Verwendung von treprostinil zur verbesserung der nierenfunktion |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| EP1625856A1 (en) | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Hydrogel polymeric conjugates of a prodrug |
| CN102648916A (zh) | 2007-02-09 | 2012-08-29 | 联合治疗公司 | 用于间质性肺病和哮喘的曲前列尼治疗 |
| PL2173890T3 (pl) * | 2007-06-21 | 2011-07-29 | Univ Muenchen Tech | Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro |
| PT3050576T (pt) | 2008-04-29 | 2021-06-01 | Ascendis Pharma Growth Disorders Div A/S | Compostos recombinantes e peguilados da hormona de crescimento humana |
| WO2010014258A2 (en) | 2008-08-01 | 2010-02-04 | Nektar Therapeutics Al, Corporation | Conjugates having a releasable linkage |
| CN102159250B (zh) * | 2008-08-11 | 2014-08-06 | 尼克塔治疗公司 | 多臂的聚合烷酸酯偶联物 |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| WO2010068754A2 (en) * | 2008-12-10 | 2010-06-17 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of medicaments to the lungs |
| CN102481331B (zh) * | 2009-06-08 | 2017-09-22 | 阿穆尼克斯运营公司 | 葡萄糖调节多肽及其制备和使用方法 |
| HUE052816T2 (hu) * | 2009-07-31 | 2021-05-28 | Ascendis Pharma As | Biológiailag lebontható polietilénglikol bázisú vízoldható hidrogélek |
| US20130053405A1 (en) | 2009-10-06 | 2013-02-28 | Ulrich Hersel | Carrier linked paliperidone prodrugs |
| HK1198359A1 (en) * | 2011-08-12 | 2015-04-10 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
-
2012
- 2012-08-10 HK HK14111870.6A patent/HK1198359A1/xx unknown
- 2012-08-10 US US14/238,437 patent/US9561287B2/en active Active
- 2012-08-10 CA CA2843883A patent/CA2843883C/en not_active Expired - Fee Related
- 2012-08-10 KR KR1020147006343A patent/KR101997939B1/ko not_active Expired - Fee Related
- 2012-08-10 EP EP12748194.3A patent/EP2741781A1/en not_active Withdrawn
- 2012-08-10 JP JP2014524413A patent/JP6092867B2/ja not_active Expired - Fee Related
- 2012-08-10 CN CN201280049725.9A patent/CN103857413A/zh active Pending
- 2012-08-10 BR BR112014003225A patent/BR112014003225A2/pt not_active Application Discontinuation
- 2012-08-10 MX MX2014001497A patent/MX349950B/es active IP Right Grant
- 2012-08-10 IN IN989CHN2014 patent/IN2014CN00989A/en unknown
- 2012-08-10 WO PCT/EP2012/065745 patent/WO2013024052A1/en not_active Ceased
- 2012-08-10 AU AU2012296954A patent/AU2012296954B2/en not_active Ceased
-
2014
- 2014-01-29 IL IL230712A patent/IL230712A/en active IP Right Grant
- 2014-02-10 ZA ZA2014/00977A patent/ZA201400977B/en unknown
-
2017
- 2017-01-27 US US15/418,180 patent/US10729778B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012296954A1 (en) | 2014-02-20 |
| KR20140070545A (ko) | 2014-06-10 |
| WO2013024052A1 (en) | 2013-02-21 |
| EP2741781A1 (en) | 2014-06-18 |
| US20190105400A1 (en) | 2019-04-11 |
| ZA201400977B (en) | 2017-11-29 |
| IN2014CN00989A (enExample) | 2015-04-10 |
| CN103857413A (zh) | 2014-06-11 |
| IL230712A0 (en) | 2014-03-31 |
| US9561287B2 (en) | 2017-02-07 |
| IL230712A (en) | 2017-08-31 |
| AU2012296954B2 (en) | 2016-09-15 |
| MX2014001497A (es) | 2014-04-25 |
| CA2843883A1 (en) | 2013-02-21 |
| HK1198359A1 (en) | 2015-04-10 |
| US20140296150A1 (en) | 2014-10-02 |
| US10729778B2 (en) | 2020-08-04 |
| JP6092867B2 (ja) | 2017-03-08 |
| MX349950B (es) | 2017-08-22 |
| CA2843883C (en) | 2020-04-28 |
| KR101997939B1 (ko) | 2019-07-08 |
| JP2014527050A (ja) | 2014-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| JO3091B1 (ar) | مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها | |
| CL2013001340A1 (es) | Compuestos derivados de isoindol-amida, pirrolo-piridin-amida y pirrolo-pirimimidin-amida, inhibidores de nampt y rock; composicion farmaceutica; y metodo para tratar hiperetension, insuficiencia cardiaca cronica, aterosclerosis, asma, enfermedad de alzheimer, enfermedad de parkinson y glaucoma, entre otras enfermedades. | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| BR112013030894A2 (pt) | moduladores do sistema imune | |
| BR112012033689A2 (pt) | derivados de ácido 2-quinolinil-acético como compostos de hiv antivirais | |
| BR112014016165A8 (pt) | compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112015009395A2 (pt) | processo para preparação de derivados do ácido biliar | |
| EA201390917A1 (ru) | Дигетероарильные соединения в качестве ингибиторов vps34 | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| BR112014014452A2 (pt) | derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| BRPI1014802B8 (pt) | profármacos de triptolida. | |
| WO2012116176A3 (en) | Asymmetric ureas and medical uses thereof | |
| BR112015010791A2 (pt) | moduladores de gpr40 de di-hidropirazol | |
| BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
| WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| BR112014008783A2 (pt) | compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório | |
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| UY33453A (es) | Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| BR112013029416A2 (pt) | derivados de indol substituídos para o tratamento de distúrbios imunológicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/60 (2017.01), A61K 47/64 (2017.01), A61P 1 |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |